ELAN'S move to merge its drug technologies business with US firm Alkermes finally allows the Irish company to shed most of its debt load and leaves it as a pure neuroscience play. Will this entice Johnson and Johnson, which already owns 50.1 per cent of Elan's Alzheimer's unit, to launch a bid for the Irish company?
